Janney Montgomery Scott Starts Jazz Pharmaceuticals (JAZZ) at Neutral
- Apple (AAPL) Tops Q4 EPS by 2c; Issues Solid Outlook
- Wall Street slips on earnings; Apple falls late after results
- Chipotle Mexican Grill (CMG) Posts Q3 EPS of $0.27; Comps Miss Views; Additional Stock Buyback Approved
- Pandora (P) Misses Q3 EPS by 1c, Q4 Revenue Guidance Falls Short
- After-Hours Movers 10/25: (OGXI) (AKAM) (VRTX) Higher; (EW) (NUVA) (CMG) (AAPL) Lower (more...)
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Janney Montgomery Scott initiated coverage on Jazz Pharmaceuticals (NASDAQ: JAZZ) with a Neutral rating.
Shares of Jazz Pharmaceuticals closed at $129.96 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Oppenheimer Starts Nutanix (NTNX) at Outperform
- UPDATE: UBS Upgrades Swift Transportation (SWFT) to Buy
- UPDATE: Stifel Starts Tabula Rasa Healthcare (TRHC) at Buy
Create E-mail Alert Related CategoriesNew Coverage
Related EntitiesJanney Montgomery Scott
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!